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Abstract
The Eastern Mediterranean is among the regions where sickle cell disease (SCD) is common. The morbidity and mortality of this
disease can be postponed to adulthood through therapies implemented in childhood. The present study focuses on the organ
damage-reducing effects of the Baskent Sickle Cell Medical Care Development Program (BASCARE), which was developed by a
team who lives in this region and has approximately 25 years of experience. The deliverables of the program included the
development of an electronic health recording system (PRANA) and electronic vaccination system; the use of low citrate infusion in
routine prophylactic automatic erythrocyte exchange (ARCE) programs including pregnant women; the use of leukocyte-filtered and
irradiated blood for transfusion; the use of magnetic resonance imaging methods (T2
∗
) for the management of transfusion-related
hemosiderosis; and the implementation of an allogeneic hematopoietic stem cell transplantation protocol for adult patients. The
sample was composed of 376 study subjects and 249 control subjects. The hospital’s Data Management System and the central
population operating system were used for data collection. BASCARE enabled better analysis and interpretation of complication and
mortality data. Vaccination rates against influenza and pneumococcal disease improved (21.5% vs 50.8% and 21.5% vs 49.2%,
respectively). Effective and safe ARCEwith low citrate infusion weremaintained in 352 subjects (1003 procedures). Maternal and fetal
mortality was prevented in 35 consecutive pregnant patients with ARCE. Chelating therapy rates reduced from 6.7% to 5%.
Successful outcomes could be obtained in all 13 adult patients who underwent allogeneic peripheral stem cell transplantation from a
fully matched, related donor. No patients died by day 100 or after the first year. Cure could be achieved without graft loss, grades III to
IV acute graft versus host disease, extensive chronic graft versus host disease, or other major complications. The BASCARE program
significantly improved patient care and thereby prolonged the life span of SCD patients (42 ± 13 years vs 29±7 years, P< .001). We
may recommend using such individualized programs in centers that provide health care for patients with SCD, in accordance with
holistic approach due to the benign nature but malignant course of the disease.
Abbreviations: ARCE = automatized erythrocyte exchange procedure, BASCARE = Baskent Sickle Cell Medical Care
Development Program, GVHD = graft vs host disease, Hgb = hemoglobin, SCD = sickle cell disease.
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disease[1]1. Introduction
Sickle cell disease (SCD) is a single-gene disease responsible for
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1to crystallize. The disease is common worldwide. Hemoglobin
(Hgb) S incidence was reported to be 10% in the Eastern
Mediterranean, namely, in Turkey.[2,3] Painful crises, hemolytic
anemia, and organ damage associated with this condition lead to
morbidity and mortality.[3,4] Hemoglobinopathy centers, state
hospitals, and university hospitals established in the regions
where this disease is prevalent are responsible for detection of the
disease and the arrangement of educational activities, as well as
building awareness and delivering therapies (mainly transfusion
therapies, in accordance with current guidelines).[5]
Hydroxyurea treatment and improved medical care reduce
mortality in childhood; however, organ damage and mortality
are merely postponed to adulthood.[6–8] It is clear that
interventions are needed to reduce mortality and morbidity in
adults. To the best of our knowledge, a limited number of data
systems for assessing organ damage, determining patient work-
flow according to management plans, and ensuring data
reliability are available.[6,9] Transfusion policies, which can
reduce maternal and fetal losses, may vary among centers.[8,10]
Allo-immunization continues to be problematic, despite the
development of methods to detect erythrocyte antigens.[11–13]
While ferritin levels and trends are widely used for reflecting iron
[14]
Figure 1. Chronological development of PRANA and data assessment.
PRANA yields specific and standard data for sickle cell disease obtained during
routine daily clinical practice. Whereas data for control group are collected from
routine hospital electronic medical record system contains medical and clinical
data gathered in provider offices.
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Therefore, it is challenging to standardize the chelating therapy
and follow-up procedures. Challenges persist in allogeneic
transplantation protocols in adults, particularly engraftment
problems and graft loss risk.[15] Performing the holistic approach
through implementation of a program which facilitates patient
follow-up and thereby improves patient care may reduce
morbidity and mortality.
The present study evaluated data from the Baskent Medical
Care Development Program for Sickle Cell Disease (BASCARE),
which was developed by an integrated medical team who have
been working in the Eastern Mediterranean for the past 25 years
to overcome the challenges of managing SCD.
2. Materials and methods
2.1. Study plan
This work was designed as a single center, and retrospective chart
review including the data between January 2004 and January
2017. A total of 376 patients (155 females) between 17 and 52
years of age who were born in the Eastern Mediterranean
consisted of PRANA group. Control group was composed of 249
patients who were being treated by the center but who did not
meet regular follow-up criteria. All patients were of Eti–Turk
origin and had been diagnosed with homozygous Hgb S or
heterozygous combinations of Hgb S and thalassemia (Hgb S-b
thalassemia and Hgb S-a thalassemia) by hemoglobin electro-
phoresis or genetic analysis, and had been regular clients. Patients
with Hgb S-a thalassemia may present with as severe as clinical
manifestations with homozygous patients probably resulting
from racial characteristics. Thus, 2 patients presenting with
severe painful crisis and hemolysis in pregnancy were not
excluded.
The BASCARE program was developed by four hematologists
who had been working at our hospital for at least 10 years (HO,
CB, MY, MK), one physiologist (IK), and one family physician
(SA), with the aim of improving medical care for SCD patients.
The deliverables of the program and dates of onset were as
follows: development of electronic recording system in accor-
dance with international accreditation rules (PRANA) and
electronic vaccination schedule (beginning from 2012); use of
low citrate for automated erythrocyte exchange (ARCE)
procedures (2004); implementation of routine prophylactic
exchange program for pregnant patients (2008); use of
leukocyte-filtered and irradiated blood for blood transfusion
(2006); use of magnetic resonance imaging methods for
management of transfusion-related hemosiderosis (T2-weighted)
(2008), and development of an allogeneic stem cell transplanta-
tion (ASCT) regimen for adult patients (2014).
Comparisons between subgroups of PRANA group and
control group are presented in Figure 1.
For subgroup analyses, the effectiveness of PRANA systemwas
investigated through checking data of 249 out of 376 patients
and the results were compared with those of 196 patients who
had been followed-up at the center before the implementation of
PRANA system. Ninety-three patients whose electronic vaccina-
tion schedule could be reached were used to evaluate the
effectiveness of the system. As expected, use of low citrate for
ARCE procedures was evaluated in a total of 352 patients
including both study and control subjects, only observational
data are presented due to missing data before 2004. The
procedure was evaluated in 35 pregnant women who underwent
prophylactic exchange and in 13 control subjects. The effective-2ness of transfusion policy and chelating therapy were investigated
by comparing data before and after commencement of the
procedures. Observational outcomes of 13 adult SCD patients
who underwent ASCT are reported. As a consequence of these
improvement efforts, overall mortality age was compared
between 376 study and 249 control subjects.
The primary end-point of our study was comparing age at
death between the patients who were enrolled and not enrolled in
the BASCARE program. The secondary end-points were the time
to reach the system to obtain required data and the rates of use for
international side effect and complication terminology supported
by objective evidence; vaccination rates; clinical effectiveness and
side effects of the ARCE with low citrate infusion rate;
pregnancy-induced maternal and fetal mortality and morbidity;
allo-immunization and transfusion-related graft versus host
disease (GvHD) rates; 100-day and one-year mortality rates;
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who underwent HSCT.
All patients give consent for use of clinical and laboratory data
unless personal identity is not reported. Therefore, no additional
written or verbal consent was required from the relatives of the
dead patients as this is a retrospective chart review. Local Ethics
Committee approval was obtained prior to study commencement
(KA17/22).2.2. Data collection and reliability
Data from controls with SCD were extracted from a hospital
electronic medical system working through a database system
(AviCennaHBYS software version 1.95; Datasel, Ankara, Turkey).
Headings included ICD code of diagnosis, symptoms on presenta-
tion, history, physical examination, hematologic and biochemical
tests, radiology–endoscopy–pathology, consultations, etiology, and
treatment and progress. On the other hand, the clinical and
laboratory data of the PRANA group patients were obtained from
the modular system (PRANA) which has the properties of a
electronic health recording system developed by Baskent team in
cooperation with engineers (Nucleus, version 9.3.39; Monad
Software Company, Ankara, Turkey). Superiorities of PRANA
include providing standard data, rapid health information,
standardized patient care, standardized workflow in accordance
withqualitymanagement, and traceability.TheMinistryofHealth’s
Central Population Management System was used to confirm
mortality records.Ageatdeathwas recorded.Thedatawerechecked
by the JACIE Quality Management Data Audit Group.2.3. Definitions
The patients who come for minimum 2 controls per year during
subsequent 3 years were defined as “regular follow-up” patients.
Patients who had not required medication to treat painful
conditions for the previous 4 weeks were considered to have
“steady-state” disease. A “painful crisis” was defined as the need
for hospital admission due to pain not related to any cause other
than SCD or for the use of parenteral nonsteroidal anti-
inflammatory inhibitors, metamizol, and narcotics for the
treatment of SCD-related pain. “Nephropathy” was defined as
the presence of at least one indicator of renal dysfunction, such as
microalbuminuria (30–300mg of microalbumin per day in spot
urine) and proteinuria, hyper-echogenicity and/or thinning of the
renal cortex on ultrasonography, and low creatinine clearance.
“Pulmonary hypertension” was indirectly determined as a
tricuspid jet velocity>2.5mm/s. “Hydroxyurea use”was defined
as the regular use of at least 15mg of hydroxyurea/kg/day for at
least 1 month. “Success after ARCE” was defined as Glasgow–
Pittsburgh Cerebral Performance category 1 or 2 for neurologic
events, improvement of renal function and liver function (to
achieve a postapheresis creatinine and bilirubin value identical to
the steady-state value), or the normalization of arterial blood
pressure and partial oxygen pressure values.[16] Pain relief and
staying in steady state for 1 week was taken as success criteria for
prolonged painful crisis. Clinical improvement was the success
criteria for priapism, lung damage, and leg ulcer.2.4. Development and implementation of PRANA program
PRANA is a modular program that records data from SCD
patients in the Hospital Data Management Systems so that it can
be accessed when needed. Data were stored in the Oracle3Database 11g Enterprise ed. 11.2.0.4.064 bit database. This
program was developed not only as an electronic medical record
system, but also to enable patient follow-up and the monitoring
of workflows; it captures complications, patient/donor prepara-
tion stages, and the follow-up for patients and donors during and
after PSCT. PRANA provides rapid health information. It was
composedmainly of a patient file and a coordinator file. Themost
important parts of the program included ICD codes and risk
factors (e.g., acute hepatic necrosis, acute chest syndrome,
thrombo-embolism, allo-immunization, number of mean yearly
painful crises, nephropathy, osteo-necrosis, pre-eclampsia, and
fetal loss), and allowed users to write record details about
complications on the same line (e.g., how pulmonary hyperten-
sion was evaluated and measurement results). Performance data,
steady-state hemoglobin, leukocyte, platelet counts, management
plan, response to therapy, side effects, and complications were
also recorded according to general terminology criteria (CTCAE
v 4.0) (Fig. 2.). The coordinator file included fields for
information about council decision, stages of pretransplant
preparation for the patient and the donor, and serology of the
donor/patient, with automatically recorded consultation and
patient/donor follow-up notes.
2.5. ARCE with reduced citrate infusion rate
Two different continuous-flow apheresis systems (Cobe Spectra
Version 7.0 and SpectraOptiaVersion 7 until 2015; TerumoBCT,
Lakewood,CO, since2015)wereused to exchange60%to70%of
the patients’ red blood cells with cross-matched donor cells of the
same blood type to reduce the Hgb S level to < 30% of the total
Hgb content. Until 2008, the inlet pump flow rate and
centrifugation speed were automatically adjusted according to
preset parameters determined by each patient’s data (weight,
height, sex, and hematocrit level) duringARCE, duringwhich cells
were subjected to930g at amaximumcentrifugation speedof1800
rev min1 (Cobe Spectra Apheresis System Essential Guide). In
some patients, the inlet pump flow rate was recorded manually. A
range of 15 to 60 mL min1 was used for the flow rate, and the
centrifuge speed was established at 400 to 1800 rev min1 (up to
930g). The total blood volume was calculated according to the
patient’s body weight (70–75mL kg1), and the calculation of red
cell volume was based on hematocrit values.[2] Acid–citrate–
dextroseA solution (ACD-A) (wholeblood toACD-Aratio=15:1)
was used in all procedures. A device developed for ARCE (Spectra
Optia) was implemented after 2012, although the procedure was
performed using a low citrate infusion rate. This device objectively
showed the amount of citrate (mL) given to the patient, which had
not been shown by the Cobe Spectra. The novel device also
performed the rinse procedure automatically, instead of manually.
The target Hct level was guided by the occurrence of a
complicated pain episode and/or by the steady-state hematocrit
level noted in SCD patients who were regularly examined as
outpatients.[16,17] The patients who experienced a complicated
pain episode required hyper-transfusion, and a target Hct value of
30% to 34% after the exchange was arranged to ensure a positive
outcome.Our goal for the remaining patientswas to achieve afinal
post-exchange Hct value identical to the steady-state value.2.6. Routine prophylactic ARCE in pregnancy
The prophylactic ARCE treatment was administered in the
second and third trimesters. As the patients undergoing exchange
transfusion required negative direct and indirect antiglobulin
Figure 2. Some parts of PRANA system which is a modular program that records data from SCD patients in the Hospital Data Management Systems. The
interfaces which shows (A) disease groups, diagnoses, risk factors, disease stages, and performance status. (B) Treatment data. (C) Side effects and complications
according to CTCAE v 4.0.
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all patients. The target Hct levels were determined according to
the steady-state Hct levels of patients who were regularly
examined as outpatients. The need for RBC transfusion was
averaged according to the target Hct level. Patients who had a
complicated pain episode, characterized by clinical deterioration,
a Hgb level of < 7g/dL, leukocytosis in the absence of infection,
and an underlying pulmonary or cardiac disease required hyper-
transfusion with a target Hct of 27% to 28% after the
exchange.[17]2.7. Management of hemosiderosis
All imaging analyses were performed as previously described
with slight modifications, and a 1.5T MRI system was used for
these analyses (Avanto; Siemens, Erlangen, Germany). Briefly,
liver and myocardial measurements included T2
∗
value screen-
ings. The signal intensity of these regions for each echo time was
measured and plotted as an exponential signal decay curve. The
lower limit of normal for T2
∗
in the detection of myocardial iron
deposition has been reported to be 20 ms, and this value was used
as the cut-off in this study. A T2
∗
value of >20 ms indicated no4cardiac iron overload, while20ms indicated that such overload
had occurred. Liver iron deposition was evaluated using the R2
∗
value (R2
∗
=1000/T2
∗
). The R2
∗
value was converted to a liver
biopsy equation using the calibration curve drawn during the
study.
MRI T2
∗
measurements were carried out for patients whose
serum ferritin level was 1000mg/L or above and who regularly
receive blood transfusion. A liver iron concentration in dry tissue
of >3.2mg Fe/g was regarded as hepatic siderosis.[18–21]
Deferasirox treatment was started for patients who were found
to have tissue iron deposition (Exjade, Novartis, Switzerland).
The initial daily dose was 20mg/kg, per os. All patients required
escalation of 5 to 10mg/kg per daily dose to enable serum ferritin
to fall below the baseline. Decision for stopping chelating therapy
was supported by radiological evidence.[14]2.8. Use of actual methods in transfusion practice
Leuko-filtered red cell suspensions preserved for 1 to 7 days by
citrate–phosphate–dextrose and with an Hct level of about 75%
were used. The RBCswerematched for Rh (C, c D, e) and Kell (K)
blood group antigens to minimize allo-immunization. Simple
Table 1
Comparison of acute and chronic organ complications of sickle
cell disease by groups.
Manifestations
PRANA program
N: 275
Control
N: 49 P
Frequency of painful event, mean±SD 1.1.±0.1 1.2±0.1 .001
Kidneys, n (%) 29 (10.5) 32.6 (32.6) < .001
Lungs, n (%) 38 (13.7) 28 (56) <.001
Brain, n (%) 20 (7.3) 3 (6.1) .772
Venous thrombosis, n (%) 10 (3.6) 11 (22.4) <.001
Heart, n (%) 9 (2.9) 5 (10.2) .027
Painful event: Dactylitis; pain in the sternum/ribs; pain in the long bones; priapism; Kidneys:
Hyposthenuria; glomerular hyperfiltration; glomerulosclerosis; albuminuria; end-stage renal disease;
Lungs: Restrictive lung disease; elevated tricuspid jet velocity; pulmonary hypertension; Heart:
restrictive cardiomyopathy; Brain: Ischaemic stroke; hemorrhagic stroke; silent infarction; neurological
decline.
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ARCE could be obtained from the close relatives of the patients.
Therefore, erythrocyte bagswere irradiated using a dose of 25–50
cGy with an irradiation device that uses cesium 137. The patients
who attended and did not attend regular controls were compared
with regard to allo-immunization and transfusion-related GvHD.
2.9. Hematopoietic stem cell transplantation
The adult patients who had an indication for transplantation
underwent ASCT from an HLA-matched sibling donor using
peripheral blood. Indications for transplant included one or more
of: frequent painful crises despite hydroxyurea treatment (>2/
year), pulmonary hypertension (TRV >2.5m/s), acute neurolog-
ical attack, acute chest syndrome, silent cranial ischemia,
widespread osteo-necrosis, and allo-immunization. A protocol
that facilitated engraftment, hindered graft loss, and minimized
acute and chronic GvHD was developed owing to engraftment
and graft loss problems seen in transplants performed with
nonmyeloablative regimens. The conditioning regimen included
200 cGy TBI and Flu150/Bu 3.2/Cy29/ATG-F 30. GvHD
prophylaxis was performed with sirolimus, mycophenolate
mofetil, and post-transplant Cy (100/kg).[15]
2.10. Statistical methods
Statistical analysis was done using SPSS 17.0 (SPSS Inc., Chicago,
IL). Categorical measurements are expressed as the number and
percent, and continuous variables as the mean± standard
deviation or median and minimum–maximum, when required.
Categorical variables were compared using the x2 test or Fisher’s
exact test. Distributions were controlled in comparisons of
mortality and continuous measurements; Student’s t-test and the
Mann–Whitney U test were used in analyses of parametric and
nonparametric variables, respectively. A P value of< .05 was
considered to indicate statistical significance.
3. Results
3.1. Effectiveness of PRANA system
The BASCARE application facilitated the collection of clinical
data about SCD. When the routine hospital’s Data Management
System and electronic health recording system PRANA were
compared, the time taken to access the required data was 84.9±
39.0s versus 3.36±0.70s for steady-state hgb; 100±51s versus
2.8±0.4s for the rate of painful crisis per year; 86±53s versus 4
±1s for pulmonary hypertension; 117±67s versus 3.4±1.0 s for
bone necrosis; and 95±57s versus 3.8±1.0s for proteinuria
(P= .01 for all). The proportion of missing data decreased with
PRANA. For example, the proportion of missing data for steady-
state Hgb decreased to 18% from 42% (P= .001). This
application increased the use of common terminology criteria
for adverse events supported by objective evidence to 100%
(system included CTCAE vs 4.0 and mandated data entry). This
possibility did not exist before PRANA.
Comparison of groups with regard to acute and chronic organ
damages is presented in Table 1. Data of only 49 patients could be
reached in control group. Organ damages seem to be better
controlled in PRANA group (Table 1).
3.2. Electronic vaccination system
The electronic vaccination system menu consisted of vaccines
against influenza, pneumococcal disease, hemophilus influenza5type b, meningococcal disease, and hepatitis B, according to the
recommendations of Infectious Diseases Society of America.
HBsAg positivity was detected in 2 out of 93 cases (2.1%), anti-
HBsAg positivity was detected in 7 (7.5%), and anti-HCV
positivity in 6 (6.4%) in 2011, before this system was introduced.
Twenty patients (21.5%) were found to have been vaccinated
against pneumococcal disease and influenza. No patients had
been vaccinated against Haemophilus influenzae.
After the system had been introduced, 40 (43%) patients were
vaccinated against hepatitis B. Antibody titers against hepatitis B
became positive in 47 (50.5%) patients (>10IU/mL). When 53
patients who came for regular checks were analyzed, the numbers
with vaccination against pneumococcal disease and influenza
were found to be 29 (49.2%) and 30 (50.8%), respectively
(P< .005). Therefore, the electronic vaccination system that
notified the physician about the absence of vaccination was
effective for improving vaccination rates.3.3. ARCE with reduced citrate infusion rate
In PRANA group, a total of 352 subjects (169 F, 183M), ranging
from 15 to 58 years of age, underwent prophylactic erythrocyte
exchange with reduced citrate infusion rate. A total of 1003
procedures were performed. Indications for the procedure and
clinical success rate are shown in Table 2. Prolonged painful crisis
was the most common indication for ARCE and a statistically
significant difference was found between groups with regard to
success rate in favor of PRANA group (98.7% vs 91.0%;
P= .02). Success rate was higher in PRANA group indications
like lung damage, acute neurologic event, and leg ulcers (P= .008,
P= .010, and, P= .001, respectively).
Procedural side effects were rare and could be easily managed
(vascular access problems occurred in 10 cases [1%], vasovagal
syncope in 1 [0.09%], paresthesia in 2 [1.9%], and allergic
reaction in 15 [1.4%]). No patient exhibited anaphylaxis,
hypocalcemia, or neurological symptoms (e.g., apathy, convul-
sion, headache).3.4. Prophylactic ARCE in pregnancy
A total of 35 patients aged between 20 and 43 years of age
underwent 73 prophylactic ARCE. Nineteen patients (54.2%)
underwent 2 procedures, one in the second and one in the third
trimester. Maternal or fetal loss did not occur. HELLP syndrome
developed in 1 patient (2.3%) and vaginal hemorrhage developed
Table 2
Indications for erythrocyte exchange and comparison of success rates by groups.
PRANA
N: 352
Control
N: 49
Indication No. of exchange procedure Success rate No. of exchange procedure Success rate P
Prolonged painful crises, n (%) 392 387 (98.7) 33 30 (91.0) .002
Prophylactic exchange in pregnancy, n (%) 72 71 (98.6) 1 1 (100) N/A
Lung damage, n (%) 58 52 (89.6) 2 1 (50.0) .008
Acute neurologic event, n (%) 43 42 (97.6) 3 2 (66.6) .010
Renal damage, n (%) 4 3 (75) – N/A
Hepatic necrosis, n (%) 40 39 (97.5) 1 1 (100) N/A
Priapism, n (%) 57 54 (94.7) 3 3 (100) N/A
Preoperative preparation, n (%) 146 146 (100) 7 7 (100) N/A
Persisted leg ulcer, n (%) 180 179 (99.4) 13 12 (91.6) .016
Intrahepatic cholestasis, n (%) 101 97 (96) – –
Success rate: Pain relief and staying in steady state for 1 week was taken as success criteria for prolonged painful crisis. Success after ARCE was defined as Glasgow–Pittsburgh Cerebral Performance category 1
or 2 for neurologic events, improvement of renal function and liver function including intrahepatic cholestasis (to achieve a postapheresis creatinine and bilirubin value identical to the steady-state value). Clinical
improvement was the success criteria for priapism, lung damage, and leg ulcer.
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in 4 (11.4%) cases. Vaso-occlusive crises developed in 5 out of 13
subjects (38.5%) who did not undergo prophylactic ARCE
during pregnancy and 4 (30.7%) died. Fetal loss developed in one
(7.7%) subject and hypertension in one (7.7%) subject.3.5. Management of hemosiderosis
For hemosiderosis management, 134 radiological analyses were
done in 119 (32%) patients in PRANA group and 77 analyses in
53 (21%) controls (P= .004). As the results of these analyses,
cardiac hemosiderosis was detected in 2 (1.6%) patients in
PRANA group and in 1 (1.8%) controls (P= .920). These
numbers were 19 (14%) versus 7 (9%), respectively, in PRANA
and control groups for hepatic hemosiderosis (P= .640).
While 13 out of 195 (6.7%) patients in control group were
detected to receive iron-chelating therapy, this ratio was 19/376
(5%) in PRANA group (P= .420). These numbers represent the
patients who had started chelating therapy during the study
period and also the ones who had been already using therapy.
When these patients were evaluated using MRI T2
∗
measure-
ments, 5 (1.3%) patients in PRANA group could discontinue
chelating therapy, no data could be reached for controls as the
patients were lost to follow up.3.6. Use of actual methods in transfusion practice
Indirect antiglobulin test was applied to 240 out of 376 patients
and 30% were detected to be allo-immunized despite preparing
erythrocyte components, and using leukocyte-filtered and
irradiated blood. Transfusion-related GvHD did not develop
in any cases, despite using blood obtained from close relatives
because of socio-cultural factors.Figure 3. Comparison of age at death in the patients who were followed-up
with or without BASCARE program. BASCARE = Baskent Sickle Cell Medical
Care Development Program.3.7. Hematopoietic SCT for adult sickle cell disease
A total of 13 adult patients (5 females and 8 males) between 20
and 46 years of age underwent peripheral SCT from HLA full-
matched relatives through the BASCARE protocol. The mean
follow-up period was 15 months (range 6–33). Transplant-
relatedmortality and 1-yearmortality were both zero. In the early
period, 1 patient (7%) developed easily managed grade II acute
GvHD and infectious complications (CMV antigenemia in 46cases [30%] cases, bacterial infection in 3 [23%], and BKV
infection in 6 [46%]). Significant late complications did not
develop in any cases (unpublished data).
Three out of 13 patients has pulmonary hypertension (TRV≥
2.5) before transplant, however, control tests could not be done
as three patients did not complete 1 year after transplant.3.8. BASCARE and mortality
When the influence of the BASCARE program on crude mortality
rate was evaluated in adult SCD patients, 27 out of 376 patients
who were enrolled in the PRANA systemwere found to have died
(7.1%). Twenty-one out of 249 patients whowere not included in
this system (8.4%) died within the same period. The mean age at
death was 42±13 years (for males 21–59 years, mean age 38±13
years; for females 27–61 years, mean age 47±13 years) in the
group included in the study. On the other han6d, the mean age at
death was lower (29±7 years) in the group that was not included
in the program (for males 27–40 years, mean age 32±6 years; for
females 17–35 years; mean age 26±9 years). There was a
statistically significant difference in age at death between the
groups with regard to age at death (P< .001) (Fig. 3.).
When the groups were compared with regard to causes of
death, while the most common cause was found as acute chest
syndrome in 9 patients (33.3%) in PRANA group, this number
[29,30]
Table 3
Causes of death by groups.
Manifestations
PRANA program
N: 27
Control
N: 21 P
Acute chest syndrome, n (%) 9 (33.3) 2 (9.5) .051
Splenic sequestration, n (%) 0 4
Prolongation of painful crisis
and multiorgan failure, n (%)
2 (7.4) 2 (9.5) .790
Acute liver failure/ DIC, n (%) 2 (7.4) 1 (4.7) .700
Septic chock, n (%) 3 (11.1) 0 NA
Hemolytic crisis, n (%) 2 (7.4) 1 (4.7) .700
Gastrointestinal bleeding, n (%) 1 (3.7) 0
Cardiac failure/lung edema, n (%) 1 (3.7) 1 (4.7) .810
Pulmonary thromboembolism, n (%) 1 (3.7) 0 NA
Pneumonia, n (%) 1 (3.7) 0 NA
Pregnancy/eclampsia, n (%) 0 1 (4.7) NA
Unidentified, n (%) 5 (18.5) 13 (61.9) < .001
DIC=disseminated intravascular coagulation.
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statistically significant. Number of the cases whose cause of death
could be identified was higher in PRANA group compare to
control group (18.5% vs 61.9%; P< .001) (Table 3).4. Discussion
The clinical course of SCD is similar to that of malignant diseases,
although it is a nonmalignant disease. Microischemia and
inflammation are responsible for progressive and severe organ
damage.[7,8] The quality of life is severely impaired for patients,
owing to the occurrence of painful crises and medical
problems.[3,7,8] The mean age of mortality for the disease is 39
years.[1] A multicenter mortality study conducted in the Eastern
Mediterranean found that crude mortality was 40.1±15 (17–64)
years for females and 34.1±10 (18–54) years for males. Acute
chest syndrome, splenic sequestration, and prolonged painful
crisis-related multiorgan failure were the most common causes of
mortality.Morbidity andmortality rates varied among ethnicities
and the countries where the patients lived.[22] While a significant
difference could not be found between groups with regard to
causes of mortality, higher number of patients with identified
causes in PRANA group may be associated with regular patient
records.
Unfortunately, the vast majority of the patients cannot benefit
from current medical developments for the following reasons.
Few centers have experience with SCD patients, and patient
follow-ups may be insufficient in the centers where the disease is
not prevalent.[23–25] More importantly, SCD is a special disease
and its management requires a well-structured multidisciplinary
approach. Therefore, the absence of a special organization and
integrated team, as well as insufficient blood bank services, may
impair patient care. The attending physicians should play a role
in correctly informing hospital management. Patient-related
factors are also important, such as patient adherence to
hydroxyurea treatment.[26–28] Economic factors and emotional
problems may also make patient compliance challenging.
Laws and regulations force institutions to improve medical
care for SCD patients. The individual efforts of medical staff who
have worked with SCD patients for several years are focused
mainly on hydroxyurea treatment and the development of
transfusion policies. The main output of these efforts is the7guidelines developed for SCD management. However, the
centers are not objectively evaluated for their adherence to these
guidelines because SCD is a heterogeneous disease and requires
individual-specific treatments.
The most important deficiency in the management of these
patients is the absence of a standard workflow. Although such a
workflow may be present, its implementation is usually
inadequate. On the other hand, developments in the medical
field may not be reflected in daily practice owing to obstacles of
knowledge/experience, as well as financial and technical
problems like novel blood bank methods, apheresis, transfusion,
and stem cell transplantation techniques. An electronic recording
system developed based on patient characteristics determines the
workflow, and traceability is the most valuable tool for these
patients.[31] Here, we explored the development of a electronic
health recording system (PRANA) that meets international
accreditation rules (authorization, coding, data safety, storage,
traceability, retrospective data collection, warnings, international
terminology). This system has become integrated into the daily
routine for patient follow-up. The PRANA system also allowed
us to implement a multifunctional electronic vaccination system
that alerted physicians at the beginning of the examination and
prompted them to check the vaccination status of the patients.
Despite the improved vaccination rates in PRANA group, this
ratio could not reach 100% due to reimbursement and low
economic status of the patients.
Starting chelating therapy and disease management is an issue
that is frequently discussed. SCD is an inflammatory disease, and
elevated serum ferritin levels therefore cannot be a reliable
parameter for assessing iron overload.[18,21] Moreover, the
outcomes of chelating therapy during pregnancy are obscure, and
risks of the drugs cannot be neglected.[30] The need for
pretransplant chelating therapy, the duration of therapy, and
treatment goals have not yet been fully determined. Imaging
techniques to reveal tissue iron levels may be helpful for
preventing unnecessary drug use. As expected, MRI T2
∗
measurements could be performed in higher number of patients
in PRANA group due to being under regular control and thereby
some part of the patients could discontinue chelating therapy.
This ratio could not be obtained for control group as they lost to
follow up.
ARCE is associated with 2 major adverse events. The first is
citrate-related complications[16,17], and the second is allo-
antibody development in the late stages of disease.[13,17] Reduced
citrate infusion in the exchange protocol was shown to lead to
acceptable side effects in many procedures. Allo-immunization
continues to be a problem, despite recent developments in blood
bank techniques and transfusion medicine. Our results indicate
that subgroup analysis using leukocyte filters may be effective in
reducing allo-immunization, although it cannot fully prevent
occurrence. It must be remembered that SCD patients tend to
receive blood products from close relatives, which can lead to
transfusion-related GvHD. The use of irradiated blood may
reduce this side effect. Given that all patients in both groups
underwent reduced citrate ARCE using the same equipment by
the same team, the difference between groups in favor of PRANA
group with regard to success rate for painful crisis, acute
neurologic event, lung damage, and leg ulcer may suggest the
contribution of regular follow up and patient records to
improved patient care.
The current literature indicates that prophylactic erythrocyte
exchange may be beneficial during pregnancy.[12,17] No maternal
and fetal losses were detected in pregnant womanwhowere being
[2] Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle
Ozdogu et al. Medicine (2018) 97:6 Medicinefollowed-up in the context of the BASCARE program and who
underwent prophylactic ARCE. In the control group there were 4
maternal deaths from vasoocclusive crisis. This supports strongly
the use of some form of transfusion during the pregnancy.
The cure rate is known to be about 90% in ASCTs from HLA
full-matched relative donors to pediatric patients who have not
developed SCD-related organ damage. Reduced-intensity condi-
tioning regimens are preferred in adult patients owing to the risk
of organ damage. Recent studies have revealed that success rates
in adult transplants were close to those in children.[32–34] The
main complications in adult transplants include engraftment,
early or late graft loss due to inflammation, and hyper-
proliferative bone marrow.[15,34] Endothelial activation is also
an important characteristic of SCD.[35] Given that the endotheli-
um is the target tissue for allogeneic cells in GvHD, it is obvious
that measures to prevent GvHD are of vital importance. The
conditioning regimen and GvHD prophylaxis were intended to
overcome these 2 major challenges in the context of the
BASCARE program, and prevented mortality, grades III–IV
GvHD, and widespread cGvHD. The program is still being used
successfully. It has enabled the medical team to obtain objective
data for transplant indications through regular follow ups and
correct patient record. The success of the program may be
attributed to the suppression of inflammation before transplan-
tation, the use of a less toxic conditioning regimen, sufficient
myelosuppression, and the current post-transplant cyclophos-
phamide treatment for GvHD prophylaxis.
This study has some limitations. First is the absence of a
comparison between low citrate ARCE and control subjects.
Second is small number of transplant patients and short duration
of follow-up after ASCT. Third is large number of missing data
belonging to the former recording system supporting our
hypothesis for the need to develop a novel and improved system.
Small number of the control group in some of the analyses may
also be considered as a limitation.
In conclusion, this study showed that implementation of the
BASCARE program significantly improved the age of mortality,
the management of SCD, and consequently increased the
motivation of the medical team. The use of such programs is
strongly recommended in all centers that provide healthcare for
SCD, which is a nonmalignant disease with many of the
features of a malignant disease and has a mean age of mortality
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